Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    3 0 0 0


Joint Bone Spine
Volume 79, n° 2
pages 134-136 (mars 2012)
Doi : 10.1016/j.jbspin.2011.06.008
accepted : 16 June 2011
Nonspecific low back pain: Assessment of available medications
 

Bernard Bannwarth , Marie Kostine, Emilie Shipley
Service de rhumatologie, groupe hospitalier Pellegrin et laboratoire de thérapeutique, université Victor-Segalen, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France 

Corresponding author.
Abstract

Many medications have been evaluated for the treatment of nonspecific low back pain. The only medications proven to be more effective than a placebo in chronic low back pain are nonsteroidal antiinflammatory drugs (NSAIDs), the acetaminophen-tramadol combination, antidepressants other than selective serotonin reuptake inhibitors, and some types of spinal applications of glucocorticoids or local anesthetics. However, the efficacy of these drugs in inducing pain relief is limited, and NSAIDs are the only drugs that also improve function. Nevertheless, the outcome of nonspecific low back pain is favorable in most cases, even in placebo-treated patients. In addition, treatment effects vary dramatically across studies. One factor in this variability is the heterogeneity of patient populations. To improve the uniformity of patient populations enrolled in therapeutic trials, the selection criteria should take into account the nociceptive, dysfunctional, and possible neuropathic components of the pain syndrome.

The full text of this article is available in PDF format.

Keywords : Nonspecific low back pain, Randomized controlled trials, Analgesics, Metaanalysis




© 2011  Société française de rhumatologie@@#104156@@